MicroRNA 423 (hsa-miR-423)

MicroRNA 423 (hsa-miR-423) is a small, non-coding RNA molecule that functions as a "post-transcriptional regulator of gene expression" by binding to complementary sequences on target mRNAs, resulting in their degradation or inhibition of translation[3][5]. It has two mature forms, miR-423-3p and miR-423-5p, both of which have been implicated in multiple biological processes including cell proliferation, apoptosis, and differentiation. hsa-miR-423 is differentially expressed in various tissues and disease states, notably in cancer, cardiovascular disease (such as heart failure), renal injury, and as a biomarker for neurodevelopmental outcomes in infants[1][2][4][5]. Its circulating form, particularly miR-423-5p, is often encapsulated in extracellular vesicles, conferring stability in serum and making it a candidate biomarker for tissue injury and developmental monitoring[2][4]. Currently, there are no direct drugs targeting hsa-miR-423, but its regulatory influence on disease pathways is an area of ongoing research for potential therapeutic modulation[2][4].

Other names

MIR423MIRN423miR-423hsa-miR-423-3phsa-miR-423-5p